The use of hypolipidemic agents in patients with hyperuricemia on the background of type 2 diabetes mellitus and atherosclerosis

Diabetes mellitus (DM) is one of the most common pathologies today. According to the Federal Register of Diabetes Mellitus, the number of patients increases by about 5% every year. As a rule, the medical history is complicated by the presence of other concomitant pathologies. And this applies not only to cardiovascular diseases, but also to lipid metabolism disorders (dyslipidemia, obesity, atherosclerosis), uric acid metabolism and excretion (hyperuricemia, gout). There was a clear correlation between complications of diabetes and atherosclerosis due to an increase in uric acid levels in blood plasma. This increase can occur for several reasons. Hereditary predisposition, consumption of foods with a high content of purine compounds and further violation of their excretion, adherence to strict diets, intense physical activity. Patients, as a rule, experience severe unbearable joint pain, swelling and redness of the skin at the site of the lesion. It should be noted that asymptomatic hyperuricemia appeared not so long ago, in which uric acid levels reach critical values without obvious clinical symptoms. Hyperuricemia is another aggravating factor for patients with type 2 diabetes. It is important that such patients are characterized by polyprogmasia. And here, special attention should be paid to the interaction of drugs and the identification of additional positive pharmacological effects on concomitant pathologies. It is known that drugs from the group of statins have multiple effects. That is why the study of the full range of pharmacological effects and their possible application in practical medicine remains one of the main tasks of pharmacotherapy.